MitraClip vs Surgical Mitral Repair: Percutaneous or Open Approach?.
Transcatheter edge-to-edge repair (TEER), most commonly performed with the MitraClip device (Abbott), has emerged as a catheter-based alternative to surgical mitral valve repair for patients with significant mitral regurgitation. The MitraClip clips the anterior and posterior mitral leaflets together at the point of regurgitation, creating a double-orifice valve — analogous to the surgical Alfieri stitch but performed percutaneously without a sternotomy. The clinical role of MitraClip differs markedly between primary (degenerative) and secondary (functional) mitral regurgitation. For primary MR, surgical repair remains clearly superior — the EVEREST II trial showed higher residual MR and reoperation rates with MitraClip. For secondary MR in heart failure, the COAPT trial demonstrated a dramatic mortality benefit for MitraClip in carefully selected patients, while the MITRA-FR trial showed no benefit, highlighting the importance of patient selection. Understanding when MitraClip is an appropriate alternative to surgery — and when surgery remains the better option — requires careful evaluation of MR etiology, anatomy, ventricular function, and surgical risk.
Head-to-head comparison.
MitraClip (TEER)
MitraClip is a catheter-based device delivered through the femoral vein, across the interatrial septum, and into the left atrium. Under echocardiographic and fluoroscopic guidance, one or more clips grasp the anterior and posterior mitral leaflets at the site of regurgitation, reducing MR by creating a double-orifice valve. The procedure is performed under general anesthesia with transesophageal echocardiography guidance.
Surgical Repair
Surgical mitral valve repair through sternotomy or minimally invasive thoracotomy provides direct visualization and access to the entire mitral apparatus. Techniques include annuloplasty ring placement, leaflet resection, chordal replacement with Gore-Tex neochordae, and commissuroplasty. Surgical repair achieves the most complete and durable correction of mitral regurgitation.
Key clinical trials.
What the guidelines say.
The 2020 ACC/AHA Guidelines recommend surgical mitral repair as the standard treatment for severe primary MR in surgical candidates (Class I). TEER is recommended for symptomatic patients with severe primary MR who are at prohibitive surgical risk (Class IIa). For secondary MR in heart failure, TEER is recommended for patients meeting COAPT selection criteria (severe MR, LVEF 20-50%, LVESD <70 mm, on optimized medical therapy) at experienced centers (Class IIa). The guidelines emphasize that TEER should be performed at centers with a multidisciplinary heart valve team.
Why the Heart Team matters.
The MitraClip vs surgery decision exemplifies the Heart Team model. An interventional cardiologist evaluates TEER feasibility based on valve anatomy, MR mechanism, and device compatibility. A cardiac surgeon evaluates surgical repair feasibility and expected outcomes. An echocardiographer provides detailed anatomical assessment. A heart failure specialist optimizes medical therapy before any intervention. WhiteGloveMD provides this comprehensive multidisciplinary evaluation, ensuring patients are offered the approach that best matches their anatomy, etiology, risk profile, and clinical situation.
Surgical mitral repair remains the gold standard for primary degenerative MR, with superior durability and MR elimination. MitraClip has transformed the treatment of secondary MR in heart failure, with the COAPT trial demonstrating a remarkable survival benefit in appropriately selected patients. The key is matching the right therapy to the right patient: surgery for primary MR in surgical candidates; MitraClip for secondary MR meeting COAPT criteria or primary MR in prohibitive-risk patients.
Frequently asked questions.
Is MitraClip as good as surgery for mitral valve repair?
For primary (degenerative) MR, surgery is clearly superior — it eliminates MR more completely and durably. For secondary (functional) MR in heart failure, MitraClip has a strong evidence base (COAPT trial) and may be the preferred approach because these patients often do not benefit as much from surgery. The answer depends entirely on the type of MR.
What are the COAPT criteria?
COAPT enrolled patients with: symptomatic heart failure, severe secondary MR (EROA >30 mm2), LVEF 20-50%, LVESD <70 mm, and optimized guideline-directed medical therapy including CRT if indicated. Patients who do not meet these criteria (as in MITRA-FR) may not benefit from MitraClip.
Can MitraClip cause mitral stenosis?
Yes — placing clips reduces the mitral valve orifice area. Excessive clipping can create functionally significant mitral stenosis (MVA <1.5 cm2). Careful intraprocedural assessment of transmitral gradients is essential. This is more likely with multiple clips or inherently small valves.
What if MitraClip does not adequately reduce my MR?
If significant residual MR persists after TEER, options include additional clips (if anatomy permits), surgical mitral repair or replacement, or continued medical therapy. About 15-30% of MitraClip patients have residual moderate or greater MR, which is a limitation compared to surgical repair.
Not sure which option is right for you?
Our Heart Team evaluates your specific anatomy, risk factors, and goals to recommend the best approach. 48-hour turnaround.